三諾生物(300298.SZ):持續葡萄糖監測系統歐盟MDR認證新增適用人羣
格隆匯1月8日丨三諾生物(300298.SZ)公佈,近日收到歐盟公吿機構TüVRheinland德國萊茵的通知,公司自主研發的“持續葡萄糖監測系統”產品在原有的歐盟MedicalDevicesRegulation(EU)2017/745(簡稱“MDR”)認證中新增了2-17歲的適用人羣。公司本次持續葡萄糖監測系統產品在原有的歐盟MDR認證中新增了2-17歲的適用人羣,有助於滿足Ⅰ型糖尿病人羣的監測需求,從而更好地覆蓋了2歲及以上的人羣進行糖尿病管理,進一步增強了公司持續葡萄糖監測產品的綜合競爭力,將對公司相關產品在海外市場,特別是認可歐盟MDR認證國家的醫保市場的業務拓展起到積極促進作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.